logo
WASHINGTON POST: Five things you should know before taking Ozempic, Wegovy or Mounjaro for weight loss

WASHINGTON POST: Five things you should know before taking Ozempic, Wegovy or Mounjaro for weight loss

West Australian6 days ago
GLP-1 medications are a major breakthrough for people to shed pounds and manage conditions such as Type 2 diabetes. However, doctors say there's a perception that weight-loss drugs such as semaglutide (brand names Ozempic and Wegovy) and tirzepatide (Mounjaro) are all you need to live a healthier life.
Diet and exercise still matter, said JoAnn Manson, chief of the division of preventive medicine at Brigham and Women's Hospital in Boston.
'They remain crucial,' Dr Manson said.
'If you're not paying attention to protein intake, hydration and having regular physical activity — especially resistance training — you can end up with poor nutritional status and substantial muscle loss.'
GLP-1 drugs mimic a hormone the body produces to regulate hunger and blood sugar. The injections cut cravings for food, slow digestion and keep people feeling full for longer periods of time.
However, since the drugs affect the stomach's functions, they also can cause gastrointestinal side effects such as nausea and vomiting. Some people stop taking the drugs because of these gut symptoms.
Still, Dr Manson said, with some 'relatively straightforward' changes in behaviour, people can minimise these problems and continue using the drug.
Dr Manson is a co-author of two articles — one for clinicians and another for patients — that were recently published in JAMA Internal Medicine. Here are five things Dr Manson and her co-authors want people on these medications to know.
These medications can help someone lose around 15 to 21 per cent of their body weight. But a significant portion of that weight - up to one-fourth - can be lean body mass and muscle, Dr Manson said.
This protein can come from chicken, fish, beans, chickpeas or tofu, Dr Manson said. Aim for 1 to 1.5 grams of protein each day per kilogram (2.2 pounds) of body weight. If you don't have an appetite or are eating smaller meals, you may want to try drinking a protein shake throughout the day as a supplement.
Dr Manson and her co-authors suggest filling a plate this way: half fruits and vegetables, one-quarter protein, and the rest whole grains.
You can strengthen your muscles with bands, weights and body-weight exercises to counteract the potential loss in lean body mass, Dr Manson said.
Aim for 60 to 90 minutes of resistance training and 150 minutes of aerobic exercise, such as brisk walking, per week.
Water can help with the dehydration and constipation associated with the weight-loss drugs, said Dr Manson, who recommended 8 to 12 glasses per day. You also can eat water-rich foods such as cucumbers and watermelon to stay hydrated.
And the researchers recommend that people on GLP-1 drugs limit their intake of alcohol, caffeine, and sugary or artificially sweetened beverages.
This may help reduce your risk of heartburn. Add fibre to help with constipation, and avoid high-fat foods - or fried foods - because they can worsen feelings of nausea.
Andres J Acosta, an associate professor of medicine and a consultant in gastroenterology and hepatology at the Mayo Clinic, who has also consulted for Novo Nordisk and Eli Lilly, and has co-founded two weight-loss-associated companies, Phenomix Sciences and Gila Therapeutics, said he often finds that patients have a 'preconceived notion' that they just need to take the medication and they'll lose weight.
But the clinical trials for these weight-loss drugs included 'comprehensive programs' with lifestyle interventions for a calorie-reduced diet and exercise program.
'This perception — just take the shot and don't do anything else - is wrong. It's not going to drive real, long-term behavioural changes,' said Professor Acosta, who is a co-author of The Mayo Clinic Diet: Weight-Loss Medications Edition. 'Patients aren't going to see the outcomes that we're seeing in the trials.'
The GLP-1 medications are one tool in a broader weight-management program, Professor Acosta said. He tells people they still need to have a healthy diet, with 'a good amount of protein' and enough water to stay well hydrated.
'I like to set the expectations from the get-go,' Professor Acosta said.
'And I also tell them that not everyone is going to lose weight.'
Some people will gain back weight when they stop taking these medications, said Elizabeth Mietlicki-Baase, an associate professor of exercise and nutrition sciences at the University of Buffalo.
Researchers are interested in 'finding strategies to prevent weight regain after discontinuation,' she said.
'But we don't have a great handle on that just yet.'
(c) 2025 , The Washington Post
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How Ozempic's maker lost the weight loss fight
How Ozempic's maker lost the weight loss fight

AU Financial Review

time19 hours ago

  • AU Financial Review

How Ozempic's maker lost the weight loss fight

Until a year ago, Danish drugmaker Novo Nordisk was riding high. It had been first to market with an injectable diabetes treatment and the name Ozempic quickly became shorthand for new class of blockbuster weight loss drugs. But competition started to catch up, a new drug trial disappointed, shares and growth fell and its chief executive departed in May. Then this week a major profit warning knocked more than €60 billion ($106 billion) off its value. The company also announced that senior executive Maziar Mike Doustdar would become the new CEO.

Ozempic drugmaker just became a victim of its own success
Ozempic drugmaker just became a victim of its own success

Sydney Morning Herald

time3 days ago

  • Sydney Morning Herald

Ozempic drugmaker just became a victim of its own success

It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to potentially eradicate the insidious plague of obesity and address diabetes can be failing to meet its profit and sales expectations. But that is the dilemma faced by Ozempic and Wegovy maker Novo Nordisk. Its share price is shedding value faster than patients are shedding kilos. For blame, one need look no further than pirates and the president (Trump, of course). Novo Nordisk stunned investors on Wednesday by downgrading its earnings expectations, losing nearly a third of its share price at one point during the day's trading – that's $143 billion in value that evaporated in a couple of hours. For some context: there are plenty of spectacular drugs and treatments that have been developed over recent decades to address many of the world's serious health issues, from cancer to heart disease, but this drug tackles obesity and therefore the myriad other health conditions that stem from being overweight (such as stroke, osteoarthritis, heart disease and even some cancers). As such, it is a game-changer. These semaglutide drugs became so popular after their efficacy for weight loss became apparent that in a sense they became victims of their own success. According to the World Health Organisation, about one billion people around the globe are obese, which means the addressable market for this drug is beyond huge and skewed to Western (and therefore wealthier) economies. And that market is still growing. The number of people afflicted by obesity has doubled over the past 30 years in adults, and quadrupled in children and adolescents, the WHO says.

Ozempic drugmaker just became a victim of its own success
Ozempic drugmaker just became a victim of its own success

The Age

time3 days ago

  • The Age

Ozempic drugmaker just became a victim of its own success

It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to potentially eradicate the insidious plague of obesity and address diabetes can be failing to meet its profit and sales expectations. But that is the dilemma faced by Ozempic and Wegovy maker Novo Nordisk. Its share price is shedding value faster than patients are shedding kilos. For blame, one need look no further than pirates and the president (Trump, of course). Novo Nordisk stunned investors on Wednesday by downgrading its earnings expectations, losing nearly a third of its share price at one point during the day's trading – that's $143 billion in value that evaporated in a couple of hours. For some context: there are plenty of spectacular drugs and treatments that have been developed over recent decades to address many of the world's serious health issues, from cancer to heart disease, but this drug tackles obesity and therefore the myriad other health conditions that stem from being overweight (such as stroke, osteoarthritis, heart disease and even some cancers). As such, it is a game-changer. These semaglutide drugs became so popular after their efficacy for weight loss became apparent that in a sense they became victims of their own success. According to the World Health Organisation, about one billion people around the globe are obese, which means the addressable market for this drug is beyond huge and skewed to Western (and therefore wealthier) economies. And that market is still growing. The number of people afflicted by obesity has doubled over the past 30 years in adults, and quadrupled in children and adolescents, the WHO says.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store